-
Rolling review of VIR-7831 antibody for COVID-19 started
Rolling review of VIR-7831 antibody for COVID-19 started
-
Rolling review of VIR-7831 antibody for COVID-19 started
Rolling review of VIR-7831 antibody for COVID-19 started
EMA is starting a ‘rolling review’ of data on VIR-7831, a monoclonal antibody for the treatment of COVID-19 developed by GlaxoSmithKline and Vir Biotechnology
-
Becoming a member of a scientific advisory group
Becoming a member of a scientific advisory group
-
Becoming a member of a scientific advisory group
Becoming a member of a scientific advisory group
EMA is calling for European clinical / technical experts to express their interest in becoming members of the Scientific Advisory Groups. Deadline June 4 2021
-
Start of rolling review: COVID-19 Vaccine (Vero Cell) Inactivated
Start of rolling review: COVID-19 Vaccine (Vero Cell) Inactivated
-
Start of rolling review: COVID-19 Vaccine (Vero Cell) Inactivated
Start of rolling review: COVID-19 Vaccine (Vero Cell) Inactivated
The decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and clinical studies
-
EMA evaluating COVID-19 Vaccine Comirnaty in children aged 12-15
EMA evaluating COVID-19 Vaccine Comirnaty in children aged 12-15
-
EMA evaluating COVID-19 Vaccine Comirnaty in children aged 12-15
EMA evaluating COVID-19 Vaccine Comirnaty in children aged 12-15
EMA has started evaluating an application to extend the use of the COVID-19 vaccine Comirnaty to include young people aged 12 to 15
